Bone marrow transplants have transformed care for patients with blood cancers because donated immune cells often prevent cancer relapse by killing off residual malignant cells. One of the drawbacks of the treatment is graft-vs.-host disease — a common side effect that occurs when the transplanted cells see the recipient’s healthy tissues as foreign and attack them. These attacks can be short-lived and mild, or chronic, debilitating and even deadly.
